Skip to main content
HARBIN GLORIA PHARMACEUTICALS Co., LTD logo

HARBIN GLORIA PHARMACEUTICALS Co., LTD — Investor Relations & Filings

Ticker · 002437 ISIN · CNE100000QG8 LEI · 300300K1ZDAXM6M73U33 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,133 across all filing types
Latest filing 2023-10-26 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 002437

About HARBIN GLORIA PHARMACEUTICALS Co., LTD

https://www.gloria.cc

Harbin Gloria Pharmaceuticals Co., Ltd. focuses on the research, development, manufacturing, and commercialization of diverse pharmaceutical products. The company specializes in therapeutic areas including cardiovascular and cerebrovascular diseases, orthopedics, oncology, and metabolic disorders. Its portfolio comprises chemical drugs, biological products, and specialized injections, with key products such as Alprostadil and Deer Melon Polypeptide. The organization prioritizes technological innovation through a dedicated R&D infrastructure aimed at developing both generic and innovative medications. It maintains multiple production facilities and an extensive distribution network to supply healthcare solutions for chronic and acute conditions.

Recent filings

Filing Released Lang Actions
关联交易管理制度（2023年10月）
Governance Information Classification · 95% confidence The document is titled '关联交易管理制度' which translates to 'Related Party Transaction Management System'. It details the principles, scope, pricing, procedures, disclosure requirements, and governance related to related party transactions for the company Harbin Yuheng Pharmaceutical Co., Ltd. The content is a comprehensive internal policy or governance document outlining how related party transactions should be managed and disclosed in compliance with relevant laws and stock exchange rules. There is no indication that this is an announcement, a financial report, or a regulatory filing per se, but rather a governance framework document. It does not contain financial statements, earnings data, or voting results. It is not a report publication announcement or a certification. Therefore, the best fitting category is Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2023-10-26 Chinese
独立董事工作制度（2023年10月）
Governance Information Classification · 95% confidence The document is a detailed internal governance policy titled '独立董事工作制度' (Independent Director Work System) for Harbin Yuheng Pharmaceutical Co., Ltd. It outlines the roles, qualifications, responsibilities, and procedural rules for independent directors within the company. The content focuses on governance structure, director duties, meeting protocols, and compliance with relevant laws and stock exchange rules. There is no financial data, earnings information, or report publication announcement. The document is not a report of financial results, audit, or legal proceedings, nor is it a notice of voting results or management changes. It is a governance-related document detailing internal rules and practices for the board and independent directors. Therefore, the most appropriate classification is Governance Information (CGR). The document length (7423 characters) supports it being a full policy document rather than a brief announcement.
2023-10-26 Chinese
监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the supervisory board of Harbin Yuheng Pharmaceutical Co., Ltd. It reports on the approval of the company's 2023 third quarter report and the decision to withdraw an application for a simplified stock issuance. The document references the actual 2023 third quarter report being disclosed elsewhere (on the CNINFO website) and does not contain the financial data itself. The document is short (1015 characters) and serves as an announcement of meeting resolutions rather than the report itself. Therefore, it fits best as a Regulatory Filing (RNS) since it is a general regulatory announcement and does not fit other more specific categories like Interim Report (IR) or Capital/Financing Update (CAP) because it does not contain substantive financial data or detailed financing information itself.
2023-10-26 Chinese
关于申请撤回公司2023年度以简易程序向特定对象发行股票申请文件的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Harbin Yuheng Pharmaceutical Co., Ltd. regarding the withdrawal of its application for a simplified procedure private placement of shares in 2023. It details board and supervisory committee meetings approving the withdrawal, reasons for the withdrawal, and confirms no significant impact on operations. The document is short (1831 characters) and serves as a formal announcement of a capital raising activity withdrawal, not the actual financing report or detailed financial data. This fits the category of Capital/Financing Update (CAP), as it relates to changes in the company's financing activities and capital structure plans.
2023-10-26 Chinese
审计委员会议事规则（2023年10月）
Governance Information Classification · 95% confidence The document is titled '董事会审计委员会议事规则' which translates to 'Board Audit Committee Meeting Rules'. It details the structure, responsibilities, procedures, and governance of the audit committee within the board of directors of Harbin Yuheng Pharmaceutical Co., Ltd. It includes sections on personnel composition, duties, meeting procedures, confidentiality, and conflict of interest rules. There is no financial data, no audit report, no financial statements, nor any announcement of financial results or voting outcomes. The document is a governance-related internal rules document for the audit committee, which fits the definition of Governance Information (CGR). It is not an announcement or a report publication, but a detailed governance practice document. Therefore, the correct classification is CGR with high confidence.
2023-10-26 Chinese
股东大会议事规则（2023年10月）
Governance Information Classification · 95% confidence The document is titled as the "Rules of Procedure for the Shareholders' General Meeting" of Harbin Yuheng Pharmaceutical Co., Ltd. It details the procedures, legal basis, and regulations governing the convening, proposal submission, notification, and conduct of shareholders' meetings. It includes sections on the general principles, convening of meetings, proposals and notifications, meeting conduct, and supplementary provisions. There is no financial data, earnings information, or report content. Instead, it is a governance document outlining internal rules and procedures related to shareholder meetings. This fits the definition of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2023-10-26 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.